capital investment
Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs
US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth